Pharvaris

Pharvaris is a late-stage biopharma company based in the United States, focused on developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. The company aims to provide effective, safe, and easy-to-administer therapies that improve the standard of care for people living with HAE.